Work

Poor overall performance of the resmetirom NIT algorithm: a multinational comparison across four tertiary care centers in Germany, Türkiye, and the United States

Year: 2026

Type: conference-paper

Abstract: Background and objective: Resmetirom was recently approved in Europe as the first pharmacologic therapy for patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis stages F2–F3. Recently, a combination of NITs has been proposed to identify treatment-eligible [for full text, please go to the a.m. URL]

Source: German Medical Science (German Research Foundation)

DOI: 10.3205/26vzmnrw106

Authors: Kaya, E., Nadeem, R., Jain, A., Shah, R., Hemant, S., Kahlon, S., Nyguyen, C., Chughtai, M., Vuppalanchi, R., Sowa, J. P., Canbay, A., Yilmaz, Y., Alkhouri, N.

Institutions: Universitätsklinikum Knappschaftskrankenhaus Bochum, Ruhr University Bochum, Indiana University School of Medicine, Recep Tayyip Erdoğan University

Language: English

Topic: Liver Disease Diagnosis and Treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7165150144

FWCI:

Cites:

Cited by:

Related to: